GLPG0187
目录号: PL14863 纯度: ≥99%
CAS No. :1320346-97-1
商品编号 规格 价格 会员价 是否有货 数量
PL14863-1mg 1mg ¥1483.64 请登录
PL14863-5mg 5mg ¥4080.00 请登录
PL14863-10mg 10mg ¥5563.64 请登录
PL14863-50mg 50mg ¥13600.00 请登录
PL14863-100mg 100mg ¥18545.45 请登录
PL14863-200mg 200mg 询价 询价
PL14863-500mg 500mg 询价 询价
PL14863-10mM*1mLinDMSO 10mM*1mLinDMSO ¥5347.27 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
GLPG0187
中文别名
3-[[2,5-二甲基-6-[4-(5,6,7,8-四氢-1,8-萘啶-2-基)-1-哌啶基]-4-嘧啶基]氨基]-N-[(4-甲氧基苯基)磺酰基]-L-丙氨酸
英文名称
GLPG0187
英文别名
GLPG0187;GLPG-0187;43A5P87Z4T;(S)-3-((2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-((4-methoxyphenyl)sulfonamido)propanoic acid.;BDBM50497714;DB12297;Q27258640;(S)-3-((2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-((4-methoxyphenyl)sulfonamido)propanoic acid;(S)-3-((2,5-dim
Cas No.
1320346-97-1
分子式
C29H37N7O5S
分子量
595.71
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
GLPG0187 是广谱的 integrin 受体拮抗剂,具有抗肿瘤活性;抑制 αvβ1-integrin 的 IC50 值为 1.3 nM。GLPG0187 抑制细胞迁移体生物合成而无细胞毒性。
生物活性
GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits α v β 1 -integrin with an IC 50 of 1.3 nM. GLPG0187 inhibits migrasome biogenesis without cytotoxicity.
性状
Solid
IC50 & Target[1][2]
IC50: 1.3 nM (αvβ1)
体外研究(In Vitro)
In a solid-phase assay, GLPG0187 shows selectivity for several RGD integrin receptors with IC50s of 1.3, 3.7, 2.0, 1.4, 1.2, 7.7 nM for αvβ1, αvβ3, αvβ5, αvβ6,αvβ8, and α5β1. GLPG0187 is a potent inhibitor of osteoclastic bone resorption and angiogenesis. Treatment with GLPG0187 dose-dependently increases the E-cadherin/vimentin ratio, rendering the cells a more epithelial, sessile phenotype. GLPG0187 dose-dependently diminishes the size of the aldehyde dehydrogenase high subpopulation of prostate cancer cells. GLPG0187 treatment results in cell rounding and clumping. GLPG0187 demonstrates a dose-dependent significant reduction in tumour cell migration. GLPG0187 at all concentrations significantly reduces cell proliferation.
体内研究(In Vivo)
Blocking α v -integrins by GLPG0187 markedly reduces their metastatic tumor growth. Bone tumor burden is significantly lower and the number of bone metastases/mouse is significantly inhibited. The progression of bone metastases and the formation of new bone metastases during the treatment period is significantly inhibited. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. van der Horst G, et al. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011 Jun;13(6):516-25.
[2]. Reeves KJ, et al. Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. Int J Cancer. 2015 Apr 1;136(7):1731-40.
溶解度数据
In Vitro: DMSO : 12.5 mg/mL (20.98 mM; ultrasonic and warming and heat to 60°C)H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2